The UK has rich and diverse health data which provides exceptional opportunities for research and innovation. Despite this opportunity, the transformative potential of health data research is far from being realised in full. Only a fraction of NHS, biomedical and health-relevant data is accessible to inform research. It can take a very long time to apply for data access and have all the relevant approvals, checks and safeguards in place to do the analysis. And once data access is granted, data can of variable quality. Read this blog by Dr James Pickett, Hub Development Manager at HDR UK about creation of large, safe data sharing initiatives across the UK.
The Department for Health and Social Care (DHSC) has published a new strategy ‘Data Saves Lives: Reshaping Health and Social Care with Data’. It seeks to drive innovation and improve efficiency across the NHS, while resetting the relationship with the public on health data. Senior Policy and Public Affairs Manager, Dr Emma Lawrence, outlines what this means for the life science sector, including our growing TechBio community.
BBSRC and NC3Rs are launching a £4 million call for applications focused on next-generation non-animal technologies in bioscience research. This call aims to enhance the capacity and confidence in alternatives to in vivo models, as well as support researchers to form collaborations with SMEs and industrial partners.
Exploristics is delighted to announce the launch of the latest release of our revolutionary clinical trial simulation software, KerusCloud Spring 2022. An innovative platform that provides powerful state-of-the-art cloud-based study simulation capabilities to clinical developers of all sizes, KerusCloud tackles the complex challenges involved in designing effective clinical trials.
As UK Research and Innovation (UKRI) have published their first five-year strategy transforming tomorrow together, which aims to “capture the full benefits of our research and innovation prowess” and keep the UK competitive on a global scale, Mark Kotter takes a look at what it means for bit.bio. This comes at a time we build on our record-breaking series B funding round and reflect on our role, as part of the wider biotechnology sector, in helping the UK achieve scientific superpower status.
The Danish National Genome Center has awarded Lifebit a four-year contract to implement Lifebit’s Federated Trusted Research Environment software, Lifebit CloudOS, within Denmark's national supercomputing center.
Discovery Park, based at Sandwich in Kent, has become the first Life Science and Innovation Campus to join the Industrial Biotechnology Innovation Centre (IBioIC), further cementing its ambition to become a centre of excellence.
The ultimate aim of drug development is for patients to access lifesaving and life-enhancing new medicines, but for many of the most innovative new medicines, securing access for NHS patients is a long and difficult process. One of the most promising new areas of medicine is cell and gene therapies, which have potential to address complex diseases, including many rare diseases for which there are no effective treatments. However, these treatments face challenges in securing patient access because of high up-front cost and uncertainty about long-term outcomes.
Last week, we released new data showing that UK biotech companies continue to demonstrate they command the confidence of global venture capital(VC) investors with £453m raised in the first quarter of 2022. The first quarter is the best for UK biotech VC financing ever recorded by BIA and Clarivate and neither the US nor China enjoyed the same year on year growth. The data was covered in this weekend’s Sunday Times with analysis from our Head of Policy and Public Affairs, Dr Martin Turner.
Guest blog by Dimitrios Skaltsas, Co-Founder & Executive Director of Intelligencia, a technology company that focuses on reducing the risk of drug development with the ultimate goal of bringing novel therapies to patients faster.